Comparison and validation of three measures of quality of life in patients with pulmonary hypertension

Internal Medicine Journal

Volumn 36, Issue 11, 2006, Pages 705-710

  Chua, R ^a,b   Keogh, A M ^a   Byth, K ^a   O'Loughlin, A ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NONE   (Australia)

Author keywords

Endothelin receptors; Epoprostenol analogs and derivatives; Piperazines; Pulmonary hypertension; Quality of life

Indexed keywords

BOSENTAN; SILDENAFIL; UNIPROST;

ADULT; AGED; ARTICLE; AUSTRALIAN QUALITY OF LIFE; COMPARATIVE STUDY; DAILY LIFE ACTIVITY; EXERCISE; FEMALE; HEART CATHETER; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SHORT FORM 36; TREATMENT OUTCOME; VALIDATION PROCESS; WALKING;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; EXERCISE TOLERANCE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 33749856309     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2006.01169.x     Document Type: Article

References (27)

1. Rich S, ed. Primary Pulmonary Hypertension: Executive Summary from the World Symposium - Primary Pulmonary Hypertension, Evian, France, 6-10 Sept, 1998. World Health Organization; 1998. Available from: URL: www.who.int/ncd/cvd/ pph.html
2. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998; 352: 719-25.
3. Keogh AM, McNeil KD, Williams T, Gabbay E, Cleland LG. Pulmonary arterial hypertension: a new era in management. Med J Aust 2003; 178: 564-7.
4. Hoeper MM, Galie N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 1209-16.
5. Krum H, Liew D. Current status of endothelin blockade for the treatment of cardiovascular and pulmonary vascular disease. Curr Opin Investig Drugs 2003; 4: 298-302.
6. McLaughlin V, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N et al. Survival with first line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 218-20.
7. McLaughlin VV, Shillington A, Rixh S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-82.
8. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P et al. Long term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-88.
9. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky AI, Kimmel SE. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-50.
10. Gabbay E, McNeil K, William T, Wlodarczyk J, Seale H, Keogh A. Tracleer (bosentan) therapy in patients with pulmonary arterial hypertension: the relationship between improvements in six minute walk test (6MWT) and quality of life (QoL). Am J Respir Crit Care Med 2004; 169: A175.
11. McKenna SP, Doughty N, Pepke-Zaba J. Development of patient reported outcome measures for pulmonary arterial hypertension. Value Health 2004; 7: S39-S40.
12. Nordenfelt L. Towards a theory of happiness: a subjectivist notion of quality of life. In: Nordenfelt L, ed. Concepts and Measurement of Quality of Life in Health Care. London: Kluwer Academic Publisher; 1994; 35-57.
13. Sneed NV, Paul S, Michel Y, VanBakel A, Hendrix G. Evaluation of 3 quality of life measurement tools in patients with chronic heart failure. Heart Lung 2001; 30: 332-40.
14. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2000; 87: 235-41.
15. Konstam V, Salem D, Pouleur H, Kostis J, Gorkin L, Shumaker S et al. Baseline quality of life as a predictor of mortality and hospitalization in 5025 patients with congestive heart failure. SOLVD Investigations. Studies of left ventricular dysfunction investigators. Am J Cardiol 1996; 78: 890-95.
16. Chua R, O'Loughlin A, Keogh AM, Byth K. Comparison and validation of three quality of life instruments for the functional assessment of pulmonary arterial hypertension [abstract]. J Heart Lung Transplant 2004; 23: 5143.
17. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure Questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 1993; 71: 1106-7.
18. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure Questionnaire: reliability and validity during a randomized, double blind, placebo controlled trial of pimobendan. Am Heart J 1992; 124: 1017-25.
19. Wight JP, Edwards L, Brazier J, Walters S, Payne JN, Brown CB. The SF-36 as an outcome measure of services for end stage renal failure. Quality Health Care 1998; 7: 209-21.
20. Hopman WM, Towheed T, Anastassiades T, Tenenhouse A, Poliquin S, Berger C et al. Canadian normative data for the SF-36 health survey. Canadian Multi-center Osteoporosis Study Research Group. CMAJ 2000; 163: 265-71.
21. Hobbs FDR, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK. Impact of heart failure and left ventricular systolic dysfunction on quality of life. Eur Heart J 2002; 23: 1867-76.
22. Hawthorne G, Richardson J, Osborne R. The assessment of quality of life (AQoL) instrument: a psychometric measure of health related quality of life. Qual Life Res 1999; 8: 209-24.
23. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38: 963-74.
24. Bittner V, Weiner D, Yussuf S, Rogers WI, McIntyre KM, Bangdiwala SI et al. Prediction of mortality and morbidity with a 6 minute walk test in patients with left ventricular dysfunction. JAMA 1993; 270: 1702-7.
25. Cahalin L, Mathier M, Semigran M, Dec W, DiSalvo T. The six minute walk test predicts peak oxygen uptake and survival in patients with advanced heart failure. Chest 1996; 110: 325-32.
26. Guyatt G, Sullivan M, Thompson P, Berman LB, Townsend M, Jones NL et al. The 6 minute walk test; a new measure of exercise capacity in patients with chronic heart failure. CMAJ 1985; 132: 919-23.
27. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M et al. Clinical correlates and prognostic significance of six minute walk test in patients with primary pulmonary hypertension. Am J Respir Crit Care Med 2000; 161: 487-92.